Cellsource (4880) saw a significant drop. The company announced its financial results for the fiscal year ending October 2024 the previous day. The operating profit was 0.13 billion yen, a reduction of 89.4% compared to the previous period, and it fell significantly short of the previously forecasted 0.42 billion yen. Regarding the contract services for processing synovial-derived stem cells, it has been determined that achieving the anticipated sales will be difficult, and a contract loss provision of 273 million yen has been recorded. Starting from the fiscal year ending October 2025, the company will transition to consolidated financial statements, with an expected operating profit of 0.37 billion yen, but concerns about failing to meet the previous period's performance seem to be leading the trend.